Future directions for anti-biofilm therapeutics targeting Candida

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 3, 2014, Pages 375-382

  Nett, Jeniel E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

amphotericin B; antifungal; azole; biofilm; Candida; echinocandin; lock therapy; matrix; resistance

Indexed keywords

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; EXTRACELLULAR MATRIX; HUMANS; PROSTHESIS-RELATED INFECTIONS; QUORUM SENSING;

EID: 84894119068     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.885838     Document Type: Review

References (86)

1. O'Toole GA. To build a biofilm. J Bacteriol 2003;185(9):2687-9
2. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis 2001;7(2):277-81
3. Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol 1998;47(3):253-6
4. Passerini L, Lam K, Costerton JW, King EG. Biofilms on indwelling vascular catheters. Crit Care Med 1992;20(5):665-73
5. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004;17(2):255-67
6. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002;19(3):139-43
7. Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993;119(12):1168-74
8. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27(5):887-92
9. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
10. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20(1):133-63
11. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012;54(8):1110-22
12. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
13. Shin JH, Kee SJ, Shin MG, et al. Biofilm production by isolates of Candida species recovered from nonneutropenic comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40(4):1244-8
14. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998;42(8):1900-5
15. Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183(18):5385-94
16. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994;62(3):915-21
17. Lewis RE, Kontoyiannis DP, Darouiche RO, et al. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother 2002;46(11):3499-505
18. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003;71(8):4333-40
19. Ramage G, Vande Walle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002;46(11):3634-6
20. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(S1):S28-39
21. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995;39(9):2128-31
22. Andes D, Nett J, Oschel P, et al. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004;72(10):6023-31
23. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001;18(4):163-70
24. Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001;80(3):903-8
25. Nett J, Lincoln L, Marchillo K, et al. Putative role of beta-1, 3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 2007;51(2):510-20
26. Schinabeck MK, Long LA, Hossain MA, et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 2004;48(5):1727-32
27. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001;45(9):2475-9
28. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46(6):1773-80
29. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol 2012;2012:528521
30. Fiori B, Posteraro B, Torelli R, et al. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. Antimicrob Agents Chemother 2011;55(6):3031-5
31. Ramage G, Bachmann S, Patterson TF, et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002;49(6):973-80
32. Kumamoto CA. A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc Natl Acad Sci USA 2005;102(15):5576-81
33. Khot PD, Suci PA, Miller RL, et al. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1, 6-glucan pathway genes. Antimicrob Agents Chemother 2006;50(11):3708-16
34. La Fleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006;50(11):3839-46
35. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol 2006;55(Pt 8):999-1008
36. Mitchell KF, Taff HT, Cuevas MA, et al. Role of matrix beta-1, 3 glucan in antifungal resistance of non-albicans Candida Biofilms. Antimicrob Agents Chemother 2013;57(4):1918-20
37. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 2007;51(7):2454-63
38. Al-Fattani MA, Douglas LJ. Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Chemother 2004;48(9):3291-7
39. Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000;46(3):397-403
40. Samaranayake YH, Ye J, Yau JY, et al. In vitro method to study antifungal perfusion in Candida biofilms. J Clin Microbiol 2005;43(2):818-25
41. Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 2010;54(8):3505-8
42. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 2012;55(1):80-5
43. Vediyappan G, Rossignol T, D'Enfert C. Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans. Antimicrob Agents Chemother 2010;54(5):2096-111
44. Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 2010;202(1):171-5
45. Robbins N, Uppuluri P, Nett J, et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 2011;7(9):e1002257
46. Chen YL, Brand A, Morrison EL, et al. Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell 2011;10(6):803-19
47. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52(3):1127-32
48. Shinde RB, Chauhan NM, Raut JS, Karuppayil SM. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann Clin Microbiol Antimicrob 2012;11:27
49. Mukherjee PK, Long L, Kim HG, Ghannoum MA. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int J Antimicrob Agents 2009;33(2):149-53
50. Shuford JA, Rouse MS, Piper KE, et al. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 2006;194(5):710-13
51. Walraven CJ, Lee SA. Antifungal lock therapy. Antimicrob Agents Chemother 2013;57(1):1-8
52. Bink A, Kucharikova S, Neirinck B, et al. The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J Infect Dis 2012;206(11):1790-7
53. Yu LH, Wei X, Ma M, et al. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob Agents Chemother 2012;56(2):770-5
54. Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob Agents Chemother 2011;55(10):4834-43
55. Lafleur MD, Sun L, Lister I, et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob Agents Chemother 2013;57(8):3585-92
56. Sherry L, Jose A, Murray C, et al. Carbohydrate Derived Fulvic Acid: an in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Front Microbiol 2012;3:116
57. Coleman JJ, Okoli I, Tegos GP, et al. Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol 2010;5(3):321-32
58. Bachmann SP, Vande Walle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002;46(11):3591-6
59. Lazzell AL, Chaturvedi AK, Pierce CG, et al. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009;64(3):567-70
60. Hudson SP, Langer R, Fink GR, Kohane DS. Injectable in situ cross-linking hydrogels for local antifungal therapy. Biomaterials 2010;31(6):1444-52
61. Raad I, Hanna H, Dvorak T, et al. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother 2007;51(1):78-83
62. Sherertz RJ, Boger MS, Collins CA, et al. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006;50(5):1865-8
63. Raad I, Chatzinikolaou I, Chaiban G, et al. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother 2003;47(11):3580-5
64. Alem MA, Douglas LJ. Prostaglandin production during growth of Candida albicans biofilms. J Med Microbiol 2005;54(Pt 11):1001-5
65. Ghalehnoo ZR, Rashki A, Najimi M, Dominguez A. The role of diclofenac sodium in the dimorphic transition in Candida albicans. Microb Pathog 2010;48(3-4):110-15
66. Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001;67(7):2982-92
67. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002;68(11):5459-63
68. Uppuluri P, Chaturvedi AK, Srinivasan A, et al. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 2010;6(3):e1000828
69. Martins M, Lazzell AL, Lopez-Ribot JL, et al. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol 2012;52(4):487-91
70. Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006;95(9):1070-4
71. Taff HT, Nett JE, Zarnowski R, et al. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog 2012;8(8):e1002848
72. Nobile CJ, Nett JE, Hernday AD, et al. Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 2009;7(6):e1000133
73. Sardi JC, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013;62(Pt 1):10-24
74. Rossignol T, Kelly B, Dobson C, D'Enfert C. Endocytosis-mediated vacuolar accumulation of the human ApoE apolipoprotein-derived ApoEdpL-W antimicrobial peptide contributes to its antifungal activity in Candida albicans. Antimicrob Agents Chemother 2011;55(10):4670-81
75. Mandal SM. A novel hydroxyproline rich glycopeptide from pericarp of Datura stramonium: proficiently eradicate the biofilm of antifungals resistant Candida albicans. Biopolymers 2012;98(4):332-7
76. Pires RH, Lucarini R, Mendes-Giannini MJ. Effect of usnic acid on Candida orthopsilosis and C. parapsilosis. Antimicrob Agents Chemother 2012;56(1):595-7
77. Pires RH, Montanari LB, Martins CH, et al. Anticandidal efficacy of cinnamon oil against planktonic and biofilm cultures of Candida parapsilosis and Candida orthopsilosis. Mycopathologia 2011;172(6):453-64
78. Evensen NA, Braun PC. The effects of tea polyphenols on Candida albicans: inhibition of biofilm formation and proteasome inactivation. Can J Microbiol 2009;55(9):1033-9
79. Alviano WS, Mendonca-Filho RR, Alviano DS, et al. Antimicrobial activity of Croton cajucara Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms. Oral Microbiol Immunol 2005;20(2):101-5
80. Shuford JA, Steckelberg JM, Patel R. Effects of fresh garlic extract on Candida albicans biofilms. Antimicrob Agents Chemother 2005;49(1):473
81. Sherry L, Millhouse E, Lappin DF, et al. Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health 2013;13:47
82. Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. Development of a high-throughput Candida albicans biofilm chip. PLoS ONE 2011;6(4):e19036
83. Nett JE, Marchillo K, Spiegel CA, Andes DR. Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun 2010;78(9):3650-9
84. Johnson CC, Yu A, Lee H, et al. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect Immun 2012;80(5):1736-43
85. Wang X, Fries BC. A murine model for catheter-associated candiduria. J Med Microbiol 2011;60(Pt 10):1523-9
86. Vande Velde G, Kucharikova S, Schrevens S, et al. Towards non-invasive monitoring of pathogen-host interactions during Candida albicans biofilm formation using in vivo bioluminescence. Cell Microbiol 2013. [Epub ahead of print]